EP Patent

EP0122077A2 — Sustained absorption pharmaceutical composition

Assigned to Elan Corp PLC · Expires 1984-10-17 · 42y expired

What this patent protects

A sustained absorption theophylline-containing pellet for oral administrattion comprises a core of theophylline or a pharmacological equivalent thereof and an organic acid embedded in a polymeric material in a multilayer arrangement and an outer membrane which permits release of …

USPTO Abstract

A sustained absorption theophylline-containing pellet for oral administrattion comprises a core of theophylline or a pharmacological equivalent thereof and an organic acid embedded in a polymeric material in a multilayer arrangement and an outer membrane which permits release of the theophylline at a controlled rate in an aqueous medium. The pellet has a dissolution rate in vitro in an aqueous medium, which when measured in a basket assembly according to U.S. Pharmacopoeia XX at 37°C and 75 r.p.m., is not more than 15% of the total theophylline after 2 hours of measurement in a buffer solution at pH 7.5. Not more than 35% of the total theophylline is released after a total of 7 hours of measurement and not more than 65% of the total theophylline is released after a total of 13 hours.

Drugs covered by this patent

Patent Metadata

Patent number
EP0122077A2
Jurisdiction
EP
Classification
Expires
1984-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Elan Corp PLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.